Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muffly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen-Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai

Blood (2023) 141 (22): 2727–2737.

https://doi.org/10.1182/blood.2022018827

Published: 2023

Includes: Supplemental data

Journal Articles

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Blood (2022) 140 (Supplement 1): 7545–7547.

https://doi.org/10.1182/blood-2022-165600

Published: 2022

Journal Articles

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

Shona Philip, Robert Lowsky, Laura J. Johnston, Sally Arai, Everett H. Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Surbhi Sidana, Wen-Kai Weng, Sushma Bharadwaj, Matthew J. Frank, David B. Miklos, Melody Smith, Lori Muffly, Vaibhav Agrawal

Blood (2022) 140 (Supplement 1): 4825–4827.

https://doi.org/10.1182/blood-2022-168546

Published: 2022

Journal Articles

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes

Blood (2022) 140 (Supplement 1): 12775–12777.

https://doi.org/10.1182/blood-2022-170877

Published: 2022

Journal Articles

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 10371–10373.

https://doi.org/10.1182/blood-2022-170759

Published: 2022

Journal Articles

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

Michelle Chin, Judith A. Shizuru, Lori Muffly, Parveen Shiraz, Laura J. Johnston, Robert Lowsky, Andrew R. Rezvani, Matthew J. Frank, Sushma Bharadwaj, Wen-Kai Weng, Robert S. Negrin, David B. Miklos, Sally Arai

Blood (2022) 140 (Supplement 1): 4788–4789.

https://doi.org/10.1182/blood-2022-165547

Published: 2022

Journal Articles

Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study

Blood (2021) 138 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2021-149306

Published: 2021

Journal Articles

CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 741.

https://doi.org/10.1182/blood-2021-152145

Published: 2021

Journal Articles

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Blood (2021) 138 (Supplement 1): 98.

https://doi.org/10.1182/blood-2021-154191

Published: 2021

Journal Articles

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-142974

Published: 2020

Journal Articles

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138988

Published: 2020

Journal Articles

Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis

Juliana Craig, BA, Maria Iglesias, BS, Kristen Cunanan, PhD, Sally Arai, MD MS, Matthew J. Frank, MD PhD, Laura J. Johnston, MD, Robert Lowsky, MD FRCP, Everett H Meyer, MD PhD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Andrew R. Rezvani, MD, Judith A Shizuru, MD PhD, Surbhi Sidana, MD, W-K Weng, MD PhD, Parveen Shiraz, MD, Lori S. Muffly, MD MS

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-141489

Published: 2020

Journal Articles

Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant

Christopher Lemieux, MD, Lori S. Muffly, MD MS, Sally Arai, MD MS, Andrew R. Rezvani, MD, Surbhi Sidana, MD, Laura J. Johnston, MD, Wen-Kai Weng, MD PhD, Parveen Shiraz, MD, Matthew J. Frank, MD PhD, Everett H Meyer, MD PhD, Judith A Shizuru, MD PhD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Robert Lowsky, MD FRCP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134250

Published: 2020

Journal Articles

Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation

Olivier Veilleux, MD, Francisco Socola, MD, Sally Arai, MD MS, Robert Lowsky, MD FRCP, Judith A Shizuru, MD PhD, Parveen Shiraz, MD, Lori S. Muffly, MD MS, Laura J. Johnston, MD, Matthew J. Frank, MD PhD, Surbhi Sidana, MD, Everett H Meyer, MD PhD, Andrew R. Rezvani, MD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Wen-Kai Weng, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136493

Published: 2020

Journal Articles

CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-139087

Published: 2020

Journal Articles

Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma

Christopher Lemieux, MD, Juliana Craig, BA, David Iberri, MD, Sally Arai, MD MS, Laura J. Johnston, MD, Robert Lowsky, MD FRCP, Lori S. Muffly, MD MS, Parveen Shiraz, MD, Michaela Liedtke, MD, Andrew R. Rezvani, MD, Matthew J. Frank, MD PhD, Wen-Kai Weng, MD PhD, Everett H Meyer, MD PhD, Judith A Shizuru, MD PhD, Robert S. Negrin, MD, David B. Miklos, MD PhD, Surbhi Sidana, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-137091

Published: 2020

Journal Articles

Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142218

Published: 2020

Journal Articles

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

R. Alejandro Sica, MD, Michael A Spinner, John S Tamaresis, PhD, Ranjana H Advani, MD, Laura J Johnston, MD, Robert Lowsky, MD, Everett H Meyer, MD PhD, David B Miklos, MD PhD, Lori S Muffly, MD, Andrew R Rezvani, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Robert S. Negrin, MD, Sally Arai, MD

Blood (2019) 134 (Supplement_1): 2022.

https://doi.org/10.1182/blood-2019-131532

Published: 2019

Journal Articles

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 576.

https://doi.org/10.1182/blood-2018-99-113261

Published: 2018

Journal Articles

Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort

Michael A Spinner, MD, Vanessa E Kennedy, MD, John S Tamaresis, PhD, Philip W Lavori, PhD, Linda V Elder, BA, Sally Arai, MD, Laura J Johnston, MD, Everett H Meyer, MD PhD, David B. Miklos, MD PhD, Lori S Muffly, MD, Robert S. Negrin, MD, Andrew R Rezvani, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Richard T Hoppe, MD, Samuel Strober, MD, Robert Lowsky, MD

Blood (2018) 132 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2018-99-113597

Published: 2018

NARROW

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study

CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis

Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant

Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation

CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma

Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only